Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Obstetric and Pediatric Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1692105

The Effective Sedative Dose of Remimazolam for BIS <60 During General Anesthesia Induction Between Elderly and Non-elderly Patients-A Randomized Controlled Trial

Provisionally accepted
Jun-li  ZhengJun-li Zheng1Jie-feng  SunJie-feng Sun2Qing  HanQing Han1Si-ren  ShiSi-ren Shi1Jin  ZhouJin Zhou3Wei-long  WangWei-long Wang3Xiao-dong  HuangXiao-dong Huang4Zhen-feng  ZHOUZhen-feng ZHOU4*
  • 1Department of Anesthesiology, The first People's Hospital of Lin-ping District, Hangzhou, China
  • 2Department of Anesthesiology, Hangzhou Fu-yang Hospital of Traditional Chinese Medicine, Hangzhou, China
  • 3Zhejiang Chinese Medical University, Hangzhou, China
  • 4Department of Anesthesiology, Hangzhou Women’s Hospital, hangzhou, China

The final, formatted version of the article will be published soon.

Background There is lack research about the effect of sufentanil on the effective dose of remimazolam during general anesthesia in both elderly and non-elderly patients scheduled for day surgery. This study was conducted to estimate the 95% effective dose (ED95) of remimazolam with low dose of sufentanil for BIS <60 during general anesthesia in both elderly and non-elderly patients scheduled for day surgery. Methods Patients scheduled for elective gynecological day procedures were randomly allocated to one of four dosage groups receiving 0.1, 0.2, 0.3, or 0.4 mg/kg of remimazolam, with 25 participants per group. All patients received a concurrent intravenous dose of sufentanil (0.1 μg/kg) during anesthesia induction. Successful sedation was defined as achieving a BIS score of <60 within five minutes of remimazolam administration. The ED50 and ED95 of remimazolam for BIS <60 during general anesthesia induction were calculated. Secondary outcomes included the incidence of hypotension, respiratory depression, and adverse events. Results In elderly patients, the estimated ED50 of remimazolam was determined to be 0.156 mg/kg, with a 95% confidence interval (CI) ranging from 0.110 to 0.190 mg/kg. For non-elderly individuals, the corresponding ED50 was 0.218 mg/kg (95% CI: 0.179–0.253 mg/kg). Additionally, the dose required to achieve 95% efficacy (ED95) was calculated as 0.336 mg/kg (95% CI: 0.286-0.437 mg/kg) in the elderly cohort and 0.418 mg/kg (95% CI: 0.361-0.528 mg/kg) in the non-elderly cohort. Hypotension occurred significantly more often in elderly patients (P <0.05), but not for the incidence of bradycardia or respiratory depression between groups (P >0.05). Conclusion Under BIS monitoring during gynecological day surgery, the estimated ED95 of remimazolam with 0.1 μg/kg sufentanil was 0.336 mg/kg (95% CI: 0.286-0.437 mg/kg) for elderly patients and 0.418 mg/kg (95% CI: 0.361-0.528 mg/kg) for non-elderly patients.

Keywords: Elderly, Non-elderly, Remimazolam, Sufentanil, effective dose

Received: 25 Aug 2025; Accepted: 26 Sep 2025.

Copyright: © 2025 Zheng, Sun, Han, Shi, Zhou, Wang, Huang and ZHOU. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zhen-feng ZHOU, zhenfeng9853@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.